Moleculin Biotech

MBRXNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$9.156 M

$8.72 +3.07%

Close of 6 Nov 2026

As of 6 Nov 2026, Moleculin Biotech (MBRX) has a market capitalization of $9.16M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$0.00

#3616 by revenue

Earnings

$33.6M

#1700 by earnings

Shares outstanding

19,477,380

Latest filing cover page

P/E ratio

0.3

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#418GT BiopharmaGTBP$9.44M
#419Phio PharmaceuticalsPHIO$9.29M
#420Moleculin BiotechMBRX$9.16M
#421Curanex PharmaceuticalsCURX$9.06M
#422BullFrog AIBFRG$9.02M

Insiders buying

All insider buying →

3 open-market purchases by officers and directors of Moleculin Biotech, worth $0.00. Grants and option exercises are excluded.

Donald H. PickerChief Science Officer$0.00
173,333 shares on 3 Aug 2026 · filed 5 Aug 2026
Walter Klemp VCEO and President$0.00
533,333 shares on 3 Aug 2026 · filed 5 Aug 2026
Jonathan P. FosterChief Financial Officer$0.00
293,333 shares on 3 Aug 2026 · filed 5 Aug 2026

What if Moleculin Biotech were worth as much as…

Open the what-if tool →

Gold $28.2T

$26,892,261

Per share 3,083,975× higher

Bitcoin $1.53T

$1,455,093

Per share 166,869× higher

Apple $5.02T

$4,776,936

Per share 547,814× higher

Or at a round number

$20.0M $50.0M $100.0M $200.0M

Where these numbers come from

Share counts and financials for Moleculin Biotech are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.